COMPLETED

Multiple Sclerosis Patient Experience on Kesimpta and Ocrevus Subcutaneous Formulation

Conditions

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The study aims to compare the experiences, including injection-related reactions (IRRs) of patients newly receiving ofatumumab to those starting to receive ocrelizumab SC formulation

Official Title

Multiple Sclerosis Patient Experience on Kesimpta and Ocrevus Subcutaneous Formulation (MS-PEKOS)

Quick Facts

Study Start:2024-11-15

Study Completion:2025-09-05

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:COMPLETED

Study ID

NCT06668324

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 99 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
1. Ability to use a mobile device or computer with broadband internet access (or data streaming available) 2. Ability to read, understand, and respond in English 3. Adult aged 18 years of age or over at the time of the survey 4. Self-confirmed diagnosis of MS 5. Prescribed either OMB or OCR SC and will receive their first injection (Day 0) followed by completing the study survey between Day 1 and Day 7	1. Participated in an OMB or OCR randomized clinical trial 2. Previously treated with OMB or OCR SC 3. Cognitive impairment that impacts the patient's ability to participate in a survey study

Inclusion Criteria

Exclusion Criteria

1. Ability to use a mobile device or computer with broadband internet access (or data streaming available)
2. Ability to read, understand, and respond in English
3. Adult aged 18 years of age or over at the time of the survey
4. Self-confirmed diagnosis of MS
5. Prescribed either OMB or OCR SC and will receive their first injection (Day 0) followed by completing the study survey between Day 1 and Day 7

1. Participated in an OMB or OCR randomized clinical trial
2. Previously treated with OMB or OCR SC
3. Cognitive impairment that impacts the patient's ability to participate in a survey study

Contacts and Locations

Study Locations (Sites)

Novartis Investigative site

East Hanover, New Jersey, 07936

United States

Collaborators and Investigators

Sponsor: Novartis Pharmaceuticals

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-11-15

Study Completion Date2025-09-05

Study Record Updates

Study Start Date2024-11-15

Study Completion Date2025-09-05

Terms related to this study

Additional Relevant MeSH Terms

Multiple Sclerosis